Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery, Chief Executive Officer, and Andrew Schemick, Chief Financial Officer, will participate in the following virtual investor conferences:
Live webcasts will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for 90 days thereafter.
About Certara
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Ariane Lovell
Finn Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$8.17 |
| Daily Change: | -0.16 -1.92 |
| Daily Volume: | 1,558,315 |
| Market Cap: | US$1.300B |
November 06, 2025 October 30, 2025 September 04, 2025 August 06, 2025 August 04, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
